Last reviewed · How we verify

NCT05761002

Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts

Status unknown NA Last updated 9 March 2023
What this trial tests

NA trial testing the Quadrivalent Vaccine (Gardasil) in Human Papilloma Virus in 58 participants. Status unknown.

Timeline
1 June 2022
Primary endpoint
1 June 2023
1 July 2023

Quick facts

Lead sponsorZagazig University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment58
Start date1 June 2022
Primary completion1 June 2023
Estimated completion1 July 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Zagazig University

Who can join

Adults 20 to 60, female only, with Human Papilloma Virus or Anogenital Wart. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the relationship between HPV genotypes and treatment outcomes of intralesional immunotherapy of anogenital warts with the quadrivalent vaccine (Gardasil).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Human Papilloma Virus

Currently open trials in the same condition.

Other Zagazig University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05761002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing